NASDAQ: ORICOric Pharmaceuticals Inc Stock
$8.08-0.69 (-7.87%)
Updated Apr 24, 2024
ORIC Price
$8.08
Fair Value Price
$0.26
Market Cap
$544.40M
52 Week Low
$4.89
52 Week High
$16.65
P/E
-4.12x
P/B
2.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$100.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$86M
Beta
0.93
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ORIC Overview
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORIC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORIC ($8.08) is overvalued by 3,056.35% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORIC ($8.08) is not significantly undervalued (3,056.35%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORIC due diligence checks available for Premium users.
Be the first to know about important ORIC news, forecast changes, insider trades & much more!
ORIC News
Valuation
ORIC fair value
Fair Value of ORIC stock based on Discounted Cash Flow (DCF)
Price
$8.08
Fair Value
$0.26
Overvalued by
3,056.35%
ORIC ($8.08) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORIC ($8.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ORIC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.12x
Industry
15.69x
Market
41.27x
ORIC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.43x
Industry
5.86x
ORIC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ORIC's financial health
Profit margin
Revenue
$0.0
Net Income
-$28.3M
Profit Margin
0%
ORIC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$252.0M
Liabilities
$27.9M
Debt to equity
0.13
ORIC's short-term assets ($212.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORIC's short-term assets ($212.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORIC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORIC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.3M
Investing
$21.0M
Financing
$453.0k
ORIC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORIC vs Biotech Stocks
Oric Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.